To solve the problem, the researchers developed new variants of the editors that still edit DNA efficiently but have significantly lower RNA editing activity.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
Researchers found that both CBEs and ABEs can cause transcriptome-wide RNA edits, which has implications for the research and therapeutic uses of base editors.
This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.
This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance.
